balance equationreview2026-06-30
Difference 242261000 exceeds tolerance 2282080.000. Presentation or filing-vintage differences need review.
Revenue
$972.52M
Fiscal year ended 2026-06-30Operating income
$34.32M
Fiscal year ended 2026-06-30Free cash flow
$28.87M
Fiscal year ended 2026-06-30Astrana Health, Inc. (ASTH) reported revenue of $972.52M and net income of $19.74M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Astrana Health, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Management Consulting Services.
Income
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $972.52M | $965.10M | $950.53M | $956.05M | $654.81M | $620.39M | $665.21M | $478.71M | $486.26M | $404.36M |
| Cost of revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Gross profit | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Operating income | $34.32M | $28.53M | $18.40M | $19.21M | $20.34M | $20.58M | $720.00K | $28.42M | $30.07M | $30.14M |
| Net income | $19.74M | $14.44M | $6.00M | $373.00K | $9.42M | $6.69M | -$6.95M | $16.09M | $19.17M | $14.84M |
| Research & development | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Weighted-average diluted shares | shares 49.78M | shares 49.05M | Unavailable | shares 49.47M | shares 49.47M | shares 48.85M | Unavailable | shares 48.22M | shares 47.98M | shares 47.70M |
| Pretax income | $27.21M | $19.71M | $7.51M | $5.67M | $16.82M | $9.60M | -$1.90M | $26.81M | $31.90M | $24.00M |
| Income tax expense | $8.76M | $6.58M | $944.00K | $4.59M | $6.61M | $3.38M | $5.88M | $7.83M | $10.03M | $7.14M |
| Diluted EPS | $0.40 | $0.29 | Unavailable | $0.01 | $0.19 | $0.14 | Unavailable | $0.33 | $0.40 | $0.31 |
| Selling, general & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| General & administrative | $54.15M | $61.74M | $60.25M | $62.39M | $50.72M | $43.90M | $41.63M | $37.80M | $35.95M | $38.72M |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $400.79M | $478.38M | $429.47M | $462.23M | $339.70M | $258.52M | $288.46M | $347.99M | $325.31M | $334.80M |
| Total assets | $2.28B | $2.36B | $2.22B | $2.24B | $1.44B | $1.33B | $1.35B | $1.29B | $1.25B | $1.23B |
| Current assets | $919.16M | $1.00B | $863.31M | $883.63M | $729.15M | $613.27M | $638.50M | $596.99M | $570.35M | $538.81M |
| Total liabilities | $1.68B | $1.78B | $1.66B | $1.68B | $904.40M | $813.55M | $840.73M | $778.27M | $773.78M | $773.86M |
| Current liabilities | $747.64M | $745.37M | $615.27M | $629.93M | $459.75M | $361.27M | $365.61M | $312.93M | $309.82M | $355.27M |
| Total equity incl. NCI | $840.84M | $815.20M | $793.30M | $789.08M | $771.53M | $750.44M | $716.73M | $709.62M | $683.01M | $657.98M |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Accounts receivable | $465.08M | $467.40M | $374.46M | $381.22M | $348.73M | Unavailable | $275.99M | Unavailable | Unavailable | Unavailable |
| Goodwill | $887.00M | $874.80M | $865.30M | $863.27M | $416.92M | $416.39M | $419.25M | $409.71M | $409.58M | $410.27M |
| Long-term debt | $882.65M | $979.76M | $990.90M | $1.00B | $401.06M | $403.89M | $425.30M | $423.12M | $425.01M | $368.45M |
| Accounts payable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Cash flow
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $32.75M | $68.06M | -$2.89M | $9.96M | $90.90M | $16.63M | -$10.95M | $33.98M | $23.19M | $5.98M |
| Capital expenditures | $3.88M | $4.00M | $3.06M | $2.55M | $1.42M | $3.07M | $2.53M | $2.30M | $2.84M | $369.00K |
| Investing cash flow | -$6.23M | -$2.84M | -$1.06M | -$534.47M | -$1.08M | -$2.39M | -$33.32M | -$8.11M | -$79.92M | -$71.04M |
| Financing cash flow | -$104.07M | -$15.96M | -$26.34M | $648.49M | -$8.64M | -$44.17M | -$15.27M | -$3.19M | $47.25M | $106.35M |
| Net change in cash | -$77.55M | $49.25M | -$30.28M | $123.98M | $81.19M | -$29.94M | -$59.54M | $22.68M | -$9.48M | $41.29M |
| Stock-based compensation | $11.79M | $9.90M | $11.38M | $7.70M | $11.71M | $7.81M | $15.24M | $6.16M | $7.39M | $5.75M |
| Common dividends paid | $95.00K | $104.00K | $1.56M | $96.00K | $778.00K | $5.46M | $1.92M | $218.00K | $1.80M | $95.00K |
| Common share repurchases | $0 | $2.80M | $15.00M | $0 | $0 | $10.60M | $900.00K | $0 | Unavailable | Unavailable |
| Depreciation & amortization | $15.55M | $15.48M | $16.40M | $15.60M | $6.90M | $6.85M | $8.13M | $7.26M | $7.44M | $5.10M |
Derived
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | $28.87M | $64.06M | -$5.95M | $7.40M | $89.48M | $13.56M | -$13.48M | $31.69M | $20.35M | $5.61M |
| Gross margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Operating margin | 3.5% | 3.0% | 1.9% | 2.0% | 3.1% | 3.3% | 0.1% | 5.9% | 6.2% | 7.5% |
| FCF margin | 3.0% | 6.6% | -0.6% | 0.8% | 13.7% | 2.2% | -2.0% | 6.6% | 4.2% | 1.4% |
| SBC / revenue | 1.2% | 1.0% | 1.2% | 0.8% | 1.8% | 1.3% | 2.3% | 1.3% | 1.5% | 1.4% |
| Current ratio | 1.23x | 1.35x | 1.40x | 1.40x | 1.59x | 1.70x | 1.75x | 1.91x | 1.84x | 1.52x |
| Revenue YoY growth | 48.5% | 55.6% | 42.9% | 99.7% | 34.7% | 53.4% | 88.4% | 37.5% | 39.6% | 19.9% |
| Net margin | 2.0% | 1.5% | 0.6% | 0.0% | 1.4% | 1.1% | -1.0% | 3.4% | 3.9% | 3.7% |
| R&D / revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| CapEx / revenue | 0.4% | 0.4% | 0.3% | 0.3% | 0.2% | 0.5% | 0.4% | 0.5% | 0.6% | 0.1% |
| Long-term debt / equity | 1.05x | Unavailable | 1.25x | 1.27x | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | 32.2% | 33.4% | 12.6% | 81.0% | 39.3% | 35.2% | Unavailable | 29.2% | 31.4% | 29.8% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ASTH in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-10View SEC filing
10-Q · Filed 2026-05-08View SEC filing
10-K · Filed 2026-03-12View SEC filing
10-Q · Filed 2025-11-10View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-09View SEC filing
Reconciliation checks needing review
11 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.
balance equationreview2026-03-31
Difference 237739000 exceeds tolerance 2358827.000. Presentation or filing-vintage differences need review.
balance equationreview2025-12-31
Difference 234962000 exceeds tolerance 2218661.000. Presentation or filing-vintage differences need review.
balance equationreview2025-09-30
Difference 234351000 exceeds tolerance 2237186.000. Presentation or filing-vintage differences need review.
balance equationreview2025-06-30
Difference 233582000 exceeds tolerance 1442350.000. Presentation or filing-vintage differences need review.
balance equationreview2025-03-31
Difference 232733000 exceeds tolerance 1331256.000. Presentation or filing-vintage differences need review.
balance equationreview2024-12-31
Difference 202558000 exceeds tolerance 1354894.000. Presentation or filing-vintage differences need review.
balance equationreview2024-09-30
Difference 202512000 exceeds tolerance 1285376.000. Presentation or filing-vintage differences need review.
balance equationreview2024-06-30
Difference 204312000 exceeds tolerance 1252471.000. Presentation or filing-vintage differences need review.
balance equationreview2024-03-31
Difference 205557000 exceeds tolerance 1226277.000. Presentation or filing-vintage differences need review.
balance equationreview2023-12-31
Difference 205883000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.